Literature DB >> 18305079

Perioperative hyperinsulinaemic normoglycaemic clamp causes hypolipidaemia after coronary artery surgery.

C J Zuurbier1, F J Hoek, J van Dijk, N G Abeling, J C M Meijers, J H M Levels, E de Jonge, B A de Mol, H B Van Wezel.   

Abstract

BACKGROUND: Glucose-insulin-potassium (GIK) administration is advocated on the premise of preventing hyperglycaemia and hyperlipidaemia during reperfusion after cardiac interventions. Current research has focused on hyperglycaemia, largely ignoring lipids, or other substrates. The present study examines lipids and other substrates during and after on-pump coronary artery bypass grafting and how they are affected by a hyperinsulinaemic normoglycaemic clamp.
METHODS: Forty-four patients were randomized to a control group (n=21) or to a GIK group (n=23) receiving a hyperinsulinaemic normoglycaemic clamp during 26 h. Plasma levels of free fatty acid (FFA), total and lipoprotein (VLDL, HDL, and LDL)-triglycerides (TG), ketone bodies, and lactate were determined.
RESULTS: In the control group, mean FFA peaked at 0.76 (sem 0.05) mmol litre(-1) at early reperfusion and decreased to 0.3-0.5 mmol litre(-1) during the remaining part of the study. GIK decreased FFA levels to 0.38 (0.05) mmol litre(-1) at early reperfusion, and to low concentrations of 0.10 (0.01) mmol litre(-1) during the hyperinsulinaemic clamp. GIK reduced the area under the curve (AUC) for FFA by 75% and for TG by 53%. The reduction in total TG was reflected by a reduction in the VLDL (-54% AUC) and HDL (-42% AUC) fraction, but not in the LDL fraction. GIK prevented the increase in ketone bodies after reperfusion (-44 to -47% AUC), but was without effect on lactate levels.
CONCLUSIONS: Mild hyperlipidaemia was only observed during early reperfusion (before heparin reversal) and the hyperinsulinaemic normoglycaemic clamp actually resulted in hypolipidaemia during the largest part of reperfusion after cardiac surgery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18305079     DOI: 10.1093/bja/aen018

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  9 in total

1.  Dyslipidemia: a prospective controlled randomized trial of intensive glycemic control in sepsis.

Authors:  Sylas B Cappi; Danilo T Noritomi; Irineu T Velasco; Rui Curi; Tatiana C A Loureiro; Francisco G Soriano
Journal:  Intensive Care Med       Date:  2012-02-02       Impact factor: 17.440

2.  Catecholamine-induced lipolysis causes mTOR complex dissociation and inhibits glucose uptake in adipocytes.

Authors:  Garrett R Mullins; Lifu Wang; Vidisha Raje; Samantha G Sherwood; Rebecca C Grande; Salome Boroda; James M Eaton; Sara Blancquaert; Pierre P Roger; Norbert Leitinger; Thurl E Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-24       Impact factor: 11.205

Review 3.  Targeting hexokinase II to mitochondria to modulate energy metabolism and reduce ischaemia-reperfusion injury in heart.

Authors:  Rianne Nederlof; Otto Eerbeek; Markus W Hollmann; Richard Southworth; Coert J Zuurbier
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 4.  Effect of glucose-insulin-potassium infusion on mortality in critical care settings: a systematic review and meta-analysis.

Authors:  Michael A Puskarich; Michael S Runyon; Stephen Trzeciak; Jeffrey A Kline; Alan E Jones
Journal:  J Clin Pharmacol       Date:  2009-05-05       Impact factor: 3.126

Review 5.  Adaptive Membrane Fluidity Modulation: A Feedback Regulated Homeostatic System Hiding in Plain Sight.

Authors:  Elzbieta Izbicka; Robert T Streeper
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

6.  Metabolic effects of mulberry leaves: exploring potential benefits in type 2 diabetes and hyperuricemia.

Authors:  A Hunyadi; E Liktor-Busa; A Márki; A Martins; N Jedlinszki; T J Hsieh; M Báthori; J Hohmann; I Zupkó
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-05       Impact factor: 2.629

7.  A randomized trial of remote ischemic preconditioning and control treatment for cardioprotection in sevoflurane-anesthetized CABG patients.

Authors:  Rianne Nederlof; Nina C Weber; Nicole P Juffermans; Bas A M J de Mol; Markus W Hollmann; Benedikt Preckel; Coert J Zuurbier
Journal:  BMC Anesthesiol       Date:  2017-03-29       Impact factor: 2.217

Review 8.  Cardiac metabolism as a driver and therapeutic target of myocardial infarction.

Authors:  Coert J Zuurbier; Luc Bertrand; Christoph R Beauloye; Ioanna Andreadou; Marisol Ruiz-Meana; Nichlas R Jespersen; Duvaraka Kula-Alwar; Hiran A Prag; Hans Eric Botker; Maija Dambrova; Christophe Montessuit; Tuuli Kaambre; Edgars Liepinsh; Paul S Brookes; Thomas Krieg
Journal:  J Cell Mol Med       Date:  2020-05-08       Impact factor: 5.310

Review 9.  Diabetes, perioperative ischaemia and volatile anaesthetics: consequences of derangements in myocardial substrate metabolism.

Authors:  Charissa E van den Brom; Carolien Se Bulte; Stephan A Loer; R Arthur Bouwman; Christa Boer
Journal:  Cardiovasc Diabetol       Date:  2013-03-04       Impact factor: 9.951

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.